Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Mar 28, 2009; 15(12): 1420-1426
Published online Mar 28, 2009. doi: 10.3748/wjg.15.1420
Published online Mar 28, 2009. doi: 10.3748/wjg.15.1420
Table 1 Adverse effects of mesalamine and thiopurines in a cohort of IBD patients[18]
| Event | Number | Percentage (%) |
| Mesalamine (n = 44) | ||
| Pulmonary dysfunction | 3 | 6.8 |
| Pancreatitis | 1 | 2.2 |
| Hemolytic anemia | 1 | 2.2 |
| Intolerance to local drug vehicle | 1 | 2.2 |
| Platelet reduction | 1 | 2.2 |
| Diarrhea | 1 | 2.2 |
| Total | 8 | 17.8 |
| Thiopurines (n = 57) | ||
| Leukopenia | 10 | 17.5 |
| Hepatic damage | 5 | 8.77 |
| Infection | 4 | 7.0 |
| Pancreatitis | 4 | 7.0 |
| Idiosyncracy | 2 | 3.50 |
| Nausea | 1 | 1.75 |
| Malignancy | 1 | 1.75 |
| Total | 27 | 47 |
- Citation: Actis GC, Pellicano R, Rizzetto M, Ayoubi M, Leone N, Tappero G, Pazienza P, Rosina F. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol 2009; 15(12): 1420-1426
- URL: https://www.wjgnet.com/1007-9327/full/v15/i12/1420.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1420